Stocktoria
ICU MEDICAL INC/DE ICUI
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1992-03-31
ICU MEDICAL INC/DE financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2B | $2.4B | $2.3B | $2.3B | $1.3B | $1.3B | $1.3B | $1.4B | $1.3B | $379.4M |
| Gross profit | $822.0M | $824.8M | $739.9M | $697.8M | $491.5M | $461.5M | $471.9M | $570.0M | $426.1M | $201.4M |
| R&D expense | $87.5M | $88.6M | $85.3M | $93.0M | $47.5M | $42.9M | $48.6M | $52.9M | $51.3M | $13.0M |
| SG&A expense | $625.2M | $638.8M | $606.7M | $608.3M | $302.6M | $284.0M | $277.0M | $320.0M | $302.2M | $89.4M |
| Operating income | $42.8M | $43.0M | $22.8M | -$42.9M | $123.2M | $98.2M | $107.4M | $29.8M | -$13.3M | $82.9M |
| Interest expense | $93.3M | $106.5M | $102.7M | $70.8M | $858,000 | $1.8M | $549,000 | $709,000 | $2.0M | $118,000 |
| Income tax | $2.4M | $51.7M | -$48.6M | -$40.1M | $20.1M | $10.6M | $13.7M | -$6.4M | -$17.4M | $22.1M |
| Net income | $732,000 | -$117.7M | -$29.7M | -$74.3M | $103.1M | $86.9M | $101.0M | $28.8M | $68.6M | $63.1M |
| EPS (diluted) | $0.03 | $-4.83 | $-1.23 | $-3.11 | $4.74 | $4.02 | $4.69 | $1.33 | $3.29 | $3.66 |
| Operating cash flow | $179.8M | $204.0M | $166.2M | -$62.1M | $267.5M | $222.8M | $101.9M | $160.2M | $154.4M | $89.9M |
| Free cash flow | $91.8M | $124.7M | $82.3M | -$152.4M | $199.0M | $130.7M | $4.6M | $67.5M | $79.9M | $66.6M |
| Cash & equivalents | — | — | — | $208.8M | $552.8M | $396.1M | $268.7M | $344.8M | $290.1M | $445.1M |
| Inventory | $615.9M | $584.7M | $709.4M | $696.0M | $290.2M | $314.9M | $337.6M | $311.2M | $288.7M | $49.3M |
| Total assets | $4.1B | $4.2B | $4.4B | $4.5B | $1.9B | $1.8B | $1.7B | $1.6B | $1.5B | $704.7M |
| Shareholders' equity | $2.1B | $2.0B | $2.1B | $2.1B | $1.6B | $1.5B | $1.4B | $1.3B | $1.2B | $660.2M |
Growth · year-over-year · Revenue CAGR 21.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -6.3% | +5.4% | -0.9% | +73.2% | +3.6% | +0.4% | -9.6% | +8.3% | +240.7% | +11.0% |
| Net income growth | — | — | — | -172.0% | +18.7% | -14.0% | +250.9% | -58.1% | +8.8% | +40.2% |
| EPS growth | — | — | — | -165.6% | +17.9% | -14.3% | +252.6% | -59.6% | -10.1% | +34.1% |
| Free cash flow growth | -26.4% | +51.5% | — | -176.6% | +52.2% | +2738.6% | -93.2% | -15.6% | +20.1% | +30.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.